- 98 Downloads
Buspirone is an anxiolytic agent from the azapirone class of compounds. It differs structurally and pharmacologically from the benzodiazepines. Although the exact anxiolytic mechanism of action of buspirone is unknown, its primary pharmacological action is its binding to serotonin 5-HT1A receptors in the brain. Unlike benzodiazepines, buspirone has no demonstrated sedative effect and has little effect on psychomotor performance or cognition. In addition, animal and human studies have found little evidence that buspirone has abuse potential or dependence liability.
Recent large comparative trials have confirmed that buspirone is superior to placebo and has similar efficacy to benzodiazepines in the treatment of patients with anxiety. In comparative trials, patients receiving buspirone had reductions in Hamilton Anxiety Rating Scale (HAM-A) total scores ranging from 37 to 60%. By comparison, those receiving benzodiazepines had HAM-A total score reductions of 29 to 69%. Buspirone usually produced significant reductions in HAM-A total scores within 1 to 2 weeks of treatment initiation. Some studies have noted a faster onset of action with benzodiazepines than with buspirone, but larger, more recent trials have not confirmed this.
Buspirone has also demonstrated efficacy in patients with anxiety and coexisting alcohol (ethanol) abuse/dependence or depression. Buspirone not only reduces symptoms of anxiety in these patients but produces improvements in the comorbid disorder. In most studies, alcohol-dependent patients were significantly more likely to remain on treatment than those receiving placebo. In patients with mixed anxiety-depression, treatment with buspirone produced significant reductions in both the HAM-A and Hamilton Depression Rating Scale total scores. Buspirone produced significant improvements in the cardinal symptoms of depression (depressed mood, guilt, work and interest, anergia and diurnal variation of mood) which indicates that it may have an antidepressant effect independent of its anxiolytic activity.
In summary, recent clinical trials have verified the efficacy of buspirone in the treatment of anxiety disorders and confirmed its role as a well established alternative to benzodiazepines. Buspirone is particularly useful in patients wishing to avoid adverse effects associated with the benzodiazepines, such as sedation and performance and cognitive impairment, or those in whom abuse and dependence potential are a concern.
Although the exact anxiolytic mechanism of action of buspirone is unknown, the drug is believed to act primarily through effects on central serotonergic systems. Buspirone binds both presynaptically and postsynaptically to serotonin 5-HT1A receptors in the brain. At presynaptic receptors in the dorsal raphé, buspirone acts as a full agonist; postsynaptically, it acts as a partial agonist at 5-HT1A receptors in the hippocampus. Buspirone also has a moderate affinity for presynaptic dopamine D2 receptors. Unlike benzodiazepines, it has no effect on the γ-amino-butyric acid (GABA)—benzodiazepine complex.
Buspirone has a low potential for producing sedation or impairment of psychomotor performance and cognition. When compared with various benzodiazepines, buspirone produces significantly less daytime sedation and has less effect on tests designed to measure psychomotor performance, including driving ability. Benzodiazepines significantly impaired memory function, but buspirone had no effect.
The abuse and dependence potential of buspirone appears to be minimal. In animal drug discrimination and drug self-administration studies, buspirone had no acute subjective intoxicating or reinforcing properties. In addition, benzodiazepines were significantly more likely to be preferred to buspirone in study participants with a history of substance abuse. The dependence liability of buspirone is lower than that of benzodiazepines as measured by significantly fewer withdrawal symptoms after drug discontinuation. Furthermore, buspirone is not cross-tolerant with benzodiazepines, as evidenced by the inability of buspirone to prevent benzodiazepine withdrawal symptoms after long term treatment with these drugs.
Buspirone is well absorbed after oral administration; however, substantial first-pass metabolism reduces oral bioavailability to approximately 4%. At therapeutic dosages there is a linear relationship between dose and area under the plasma concentration-time curve (AUC). Administration of buspirone with food substantially increases the AUC.
Buspirone undergoes extensive metabolism to at least 7 major and 5 minor metabolites. Less than 1% of an administered dose is excreted unchanged in the urine. The elimination half-life of buspirone ranges from 2 to 11 hours.
The elimination of buspirone is reduced in patients with cirrhosis; however, interpatient variation is considerable. Some studies have also reported decreases in buspirone clearance in patients with renal impairment. The pharmacokinetic properties of buspirone do not appear to be changed in the elderly.
Data from several recent large comparative studies have confirmed that buspirone is superior to placebo and has equivalent efficacy to benzodiazepines in the treatment of patients with anxiety. After treatment periods of 3 to 6 weeks, buspirone 10 to 60 mg/day produced reductions in Hamilton Anxiety Rating Scale (HAM-A) total scores ranging from 37 to 60%. This compared with reductions in HAM-A total scores of 29 to 69% for patients receiving benzodiazepines. Buspirone also produced significant reductions in HAM-A total scores in a few trials in patients aged ≥ 65 years. HAM-A scores in patients receiving buspirone declined progressively over the treatment period and were usually significantly different from baseline or placebo within 1 to 2 weeks of treatment. Results of a few studies have shown that benzodiazepines have a faster onset of effect than buspirone, although this was not confirmed in recent, larger studies. Buspirone is effective in alleviating both the psychic and the somatic symptoms of anxiety; however, psychic symptoms generally declined first. Studies evaluating the long term efficacy of buspirone have confirmed that the drug is effective after treatment periods lasting up to 1 year.
Patients with anxiety and co-existing alcohol (ethanol) use disorders receiving buspirone were significantly more likely to remain on treatment than those receiving placebo in 3 of 4 studies. In these studies, buspirone also produced significantly greater reductions in anxiety and alcohol consumption than placebo.
The addition of buspirone to treatment with selective serotonin reuptake inhibitors (SSRIs) in patients with major depression who had failed to respond, or had partially responded, to an adequate trial with an SSRI improved depressive symptoms. Preliminary studies suggest that buspirone may be useful in the treatment of agitation in patients with dementia.
In patients with mixed anxiety-depression, buspirone was significantly superior to placebo in reducing HAM-A total scores. It was also associated with significant reductions in Hamilton Depression Rating Scale (HAM-D) total scores. Significant reductions in the cardinal symptoms of depression (depressed mood, guilt, work and interest, anergia and diurnal variation of mood) in patients receiving buspirone indicated that the drug has intrinsic antidepressant properties.
Preliminary studies of the use of buspirone in other indications such as smoking cessation and of buspirone alone or combined with an SSRI in obsessive-compulsive disorder have been conducted. Results of these studies were inconclusive, and further research is needed to establish whether buspirone has a role in these conditions.
Buspirone is generally well tolerated. In pooled data from 17 clinical trials, the most commonly reported adverse events not seen at equivalent incidence in placebo recipients include dizziness, nausea, headache, nervousness, lightheadedness and dry mouth. However, the frequencies of drowsiness, insomnia and excitement were similar to those reported in patients receiving placebo. Neither age nor duration of treatment appears to affect the frequency of adverse events. There have been rare case reports of buspirone-induced psychological (psychosis, mania, panic attack) and neuromuscular (dystonia, dyskinesia) adverse events.
Data concerning the effects of buspirone overdose are limited; however, the drug appears to produce relatively mild symptoms. There are no reported deaths after overdose when buspirone was the sole ingestant.
Dosage and Administration
Buspirone should be initiated at a dosage of 15 mg/day, administered in 2 divided doses. The target therapeutic dosage is 30mg daily, which can be achieved by the second week of treatment. Maximum dosage is 45mg daily in the UK and 60 mg/day in the US. Dosage adjustments may be necessary in patients with severe hepatic or renal dysfunction, as there is some decreased elimination of buspirone in such patients (although interpatient variation is considerable). Dosage adjustments in the elderly do not appear to be necessary.
No pharmacokinetic or pharmacodynamic interactions have been found between buspirone and tricyclic antidepressants or benzodiazepines. Buspirone should not be coadministered with monoamine oxidase inhibitors because of reports of elevated blood pressure with combined use.
KeywordsAdis International Limited Anxiety Disorder Generalize Anxiety Disorder Panic Disorder Clin Psychiatry
Unable to display preview. Download preview PDF.
- 2.Eison MS. Azapirones: mechanism of action in anxiety and depression. Drug Ther 1990 Aug; 20 Suppl.: 3–8Google Scholar
- 3.Pecknold JC. Serotonin 5-HT1a agonists: a comparative review. CNS Drugs 1994 Sep; 2: 234–51Google Scholar
- 7.Dement WC, Seidel WF, Cohen SA, et al. Effects of alprazolam, buspirone and diazepam on daytime sedation and performance. Drug Invest 1991; 3(3): 148–56Google Scholar
- 16.Bourin M, Auget JL, Colombel MC, et al. Effects of single oral doses of bromazepam, buspirone and clobazam on performance tasks and memory. Neuropsychobiology 1990 Aug; 22: 141–5Google Scholar
- 25.Lader M. Can buspirone induce rebound, dependence or abuse?. Br J Psychiatry 1991 Sep; 159 Suppl. 12: 45–51Google Scholar
- 26.Balster RL. Abuse potential of buspirone and related drugs. J Clin Psychopharmacol 1990 Jun; 10 Suppl.: 31–7Google Scholar
- 28.Troisi II JR, Critchfield TS, Griffiths RR. Buspirone and lorazepam abuse liability in humans: behavioral effects, subjective effects and choice. Behav Pharmacol 1993 Jun; 4: 217–30Google Scholar
- 30.Evans SM, Griffiths RR, de Wit H. Preference for diazepam, but not buspirone, in moderate drinkers. Psychopharmacol-ogy 1996 Jan; 123(2): 154–63Google Scholar
- 35.Dimitriou EC, Parashos AJ, Giouzepas JS. Buspirone vs alprazolam: a double-blind comparative study of their efficacy, adverse effects and withdrawal symptoms. Drug Invest 1992; 4(4): 316–21Google Scholar
- 38.Delle Chiaie R, Pancheri P, Casacchia M, et al. Assessment of the efficacy of buspirone in patients affected by generalized anxiety disorder, shifting to buspirone from prior treatment with lorazepam: a placebo-controlled, double-blind study. J Clin Psychopharmacol 1995 Feb; 15: 12–9PubMedGoogle Scholar
- 43.Datta AK, Muzzin S, Gene-Cos N, et al. Breathing during wakefulness and sleep in anxious patients with chronic obstructive airways disease: effect of buspirone anxiolysis [letter]. Thorax 1991 Oct; 46: 744PGoogle Scholar
- 46.Gregory CA, Anderson IM, Cowen PJ. Metergoline abolishes the prolactin response to buspirone. Psychopharmacology (Berl) 1990; 100: 283–4Google Scholar
- 47.Anderson IM, Cowen PJ. Effect of pindolol on endocrine and temperature responses to buspirone in healthy volunteers. Psychopharmacology (Berl) 1992 Mar; 106: 428–32Google Scholar
- 50.Gianola D, Pagani G, Montini M, et al. Neuroendocrine effects of buspirone, a new anti-serotoninergic agent [abstract]. J Endocrinol Invest 1991; 14(6 Suppl. 4): 79Google Scholar
- 51.Mayol RF, Adamson DS, Gammans RE, et al. Pharmacokinetics and disposition of 14C-buspirone HCL after intravenous and oral dosing in man [abstract no. B36]. Clin Pharmacol Ther 1985; 37(2): 210Google Scholar
- 56.Mayol RF, Gammans RE, Mackenthun AV, et al. The effect of food on the bioavailability of buspirone HC1 [abstract]. Clin Res 1983; 31(2): 631aGoogle Scholar
- 57.Bullen WW, Bivens DL, Gammans RD, et al. The binding of buspirone to human plasma proteins [abstract]. Fed Proc 1985; 44: 1123Google Scholar
- 63.Sacchetti E, Zerbini O, Banfi F, et al. Overlap of buspirone with lorazepam, diazepam and bromazepam in patients with generalized anxiety disorder: findings from a controlled, multi-centre, double-blind study. Hum Psychopharmacol 1994 Nov–Dec; 9: 409–22Google Scholar
- 72.Enkelmann R. Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharma-cology (Berl) 1991; 105(3): 428–32Google Scholar
- 73.Ansseau M, Papart P, Gérard M-A, et al. Controlled comparison of buspirone and oxazepam in generalized anxiety. Neuropsychobiology 1991 Jun; 24: 74–8Google Scholar
- 74.Joshi V, Worlikar P, Karbhari A. Effect of coffee on psychomotor effects of buspirone [abstract]. Can J Physiol Pharmacol 1994; 72 Suppl. 1: 450Google Scholar
- 75.Feighner JP, Cohn JB. Analysis of individual symptoms in generalized anxiety — a pooled, multistudy, double-blind evaluation of buspirone. Neuropsychobiology 1990 Feb; 21: 124–30Google Scholar
- 76.Buspirone: the product monograph. 2nd ed. Chester: Adis International Limited, 1996Google Scholar
- 81.Ritchie LD, Cox J. A multicentre study of buspirone in the treatment of anxiety disorders in the elderly. Br J Clin Res 1993; 4: 131–9Google Scholar
- 82.Böhm C, Robinson DS, Gammans RE, et al. Buspirone therapy in anxious elderly patients: a controlled clinical trial. J Clin Psychopharmacol 1990 Jun; 10 Suppl.: 47–51Google Scholar
- 83.Levine S, Napoliello MJ, Domantay AG. An open study of buspirone in octogenarians with anxiety. Hum Psychopharmacol 1989; 4: 51–3Google Scholar
- 85.Tollefson GD, Montague-Clouse J, Lancaster SP. Buspirone in comorbid alcohol dependency and generalized anxiety disorders. Drug Ther 1990 Aug; 20 Suppl.: 35–51Google Scholar
- 96.Schweizer E, Rickels K, Hassman H. A double-blind, placebo-controlled comparison of imipramine and buspirone in the treatment of major depression in the elderly in the community [abstract]. Psychopharmacol Bull 1994; 30(4): 639Google Scholar
- 97.Robinson DS, Rickels K, Feighner J, et al. Clinical effects of the 5-HT1a partial agonists in depression: a composite analysis of buspirone in the treatment of depression. J Clin Psychopharmacol 1990 Jun; 10 Suppl.: 67–76Google Scholar
- 98.Proulx J, Fontaine R, Dallai A. Buspirone in patients with atypical depression with panic attacks. Curr Ther Res 1991 Jul; 50: 127–32Google Scholar
- 104.West R, Hajek P, McNeill A. Effect of buspirone on cigarette withdrawal symptoms and short-term abstinence rates in a smokers clinic. Psychopharmacology (Berl) 1991; 104(1): 91–6Google Scholar
- 107.McNair DM, Lorr M. An analysis of mood in neurotics. J Abnorm Soc Psychology 1964; 69: 620–7Google Scholar
- 115.Khanna S. Double blind cross over trial of fluoxetine and buspirone in obsessive compulsive disorder [abstract]. 9th World Congress of Psychiatry: 1993 Jun 6-12; Rio de Janeiro, Brazil: 277Google Scholar
- 120.Dimitriou EC. Augmenting the effects of antidepressant medication by adding buspirone. 10th World Congress of Psychiatry: 1996 Aug 23-24; MadridGoogle Scholar
- 123.Sakauye KM, Camp CJ, Ford PA. Effects of buspirone on agitation associated with dementia. Am J Geriatr Psychiatry 1993; 1(1): 82–4Google Scholar
- 124.Herrmann N, Eryavec G. Buspirone in the management of agitation and aggression associated with dementia. Am J Geriatr Psychiatry 1993; 1(3): 249–53Google Scholar
- 125.Cantillon M, Brunswick R, Molina D, et al. Buspirone vs haloperidol. A double-blind trial for agitation in a nursing home population with Alzheimer’s disease. Am J Geriatr Psychiatry 1996; 4(3): 263–7Google Scholar
- 127.Package Insert, Mead Johnson Pharmaceuticals, A Division Bristol-Myers Squibb, Princeton, New Jersey, USA. 1995 JanGoogle Scholar
- 130.Ghazal A, Abdel Meguid AK, Egyptian Multicentre Collaborative Study Group. An open, non-comparative multicentre study of the efficacy and tolerability of buspirone in generalised anxiety and anxiety-associated symptoms. Eur J Clin Res 1996; 8: 121–31Google Scholar
- 132.Norden MJ. Buspirone treatment of sexual dysfunction associated with selective serotonin re-uptake inhibitors. Depression 1994; 2(2): 109–12Google Scholar
- 137.Mclvor RJ, Sinanan K. Buspirone-induced mania. Br J Psychiatry 1991 Jan; 158: 136–7Google Scholar
- 141.Chignon JM, Lepine JP. Panic and hypertension associated with single dose of buspirone [letter]. Lancet 1989 Jul 1; II: 46–7Google Scholar
- 146.Bernardi F, Chillotti C, Loi V, et al. Buspirone in the management of dyskinesias induced by L-dopa [abstract]. Mov Disord 1994 Mar; 9: 254Google Scholar
- 149.Neppe VM. High-dose buspirone in case of tardive dyskinesia [letter]. Lancet 1989 Dec 16; II: 1458Google Scholar
- 152.Goetz CM, Krenzelok EP, Lopez G, et al. Buspirone toxicity: a prospective study [abstract]. Ann Emerg Med 1990 Jun; 19: 630Google Scholar
- 154.Pollicino AM, Spina E, Campo GM, et al. Pharmacokinetic interactions between tricyclic antidepressants and other psy-chotropic drugs in depressed patients. Pharmacol Res 1992 May–Jun; 25 Suppl. 2: 210–1Google Scholar
- 155.Napoliello MJ. A study of buspirone coprescribed with antidepressants in 184 anxious ambulatory patients. Curr Ther Res 1986; 40: 917–23Google Scholar
- 162.Boulenger J-P, Gram LF, Jolicoeur FB, et al. Repeated administration of buspirone: absence of pharmacodynamic or pharmacokinetic interaction with triazolam. Hum Psychopharmacol 1993 Mar–Apr; 8: 117–24Google Scholar
- 164.Jann MW, Huang HF, Chang TP, et al. Lack of pharmacokinetic interaction between buspirone and haloperidol in schizophrenic patients [abstract no. P-2-1]. Eur Neuropsychopharmacol 1996; 6 Suppl. 3: 37Google Scholar
- 165.D’Souza M, Nuyen N, Archer D, et al. Cyclosporine buspirone interaction [abstract]. Pharm Res 1990 Sep; 7 Suppl.: S–253Google Scholar
- 170.Kiev A, Domantay AG. A study of buspirone coprescribed with nonsteroidal anti-inflammatory drugs in 150 anxious ambulatory patients. Curr Ther Res 1989 Dec; 46: 1086–90Google Scholar
- 172.Rickeis K, Schweizer E. The treatment of generalized anxiety disorder in patients with depressive symptomatology. J Clin Psychiatry 1993 Jan; 54 Suppl.: 20–3Google Scholar